The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Arcus Biosciences Inc COM 03969F109 51,726 1,842,077 SH   SOLE   1,842,077 0 0
Coupang Inc CL A 22266T109 225,262 4,564,571 SH   SOLE   4,564,571 0 0
Novocure Ltd ORD SHS G6674U108 46,380 350,884 SH   SOLE   350,884 0 0
Oric Pharmaceuticals Inc COM 68622P109 24,686 1,007,575 SH   SOLE   1,007,575 0 0
Oyster Point Pharma Inc COM 69242L106 50,610 2,768,586 SH   SOLE   2,768,586 0 0
Unity Biotechnology Inc COM 91381U101 6,570 1,094,998 SH   SOLE   1,094,998 0 0
Yext Inc COM 98585N106 31,085 2,146,785 SH   SOLE   2,146,785 0 0